Although agonists and antagonists of muscarinic receptors have been known for long time, there is renewed interest in compounds (such as allosteric or bitopic ligands, or biased agonists) able to differently and selectively modulate these receptors. As a continuation of our previous research, we designed a new series of dimers of the well-known cholinergic agonist carbachol. The new compounds were tested on the five cloned human muscarinic receptors (hM1–5) expressed in CHO cells by means of equilibrium binding experiments, showing a dependence of the binding affinity on the length and position of the linker connecting the two monomers. Kinetic binding studies revealed that some of the tested compounds were able to slow the rate of NMS dissociation, suggesting allosteric behavior, also supported by docking simulations. Assessment of ERK1/2 phosphorylation on hM1, hM2 and hM3 activation showed that the new compounds are endowed with muscarinic antagonist properties. At hM2 receptors, some compounds were able to stimulate GTPγS binding but not cAMP accumulation, suggesting a biased behavior. Classification, Molecular and cellular pharmacology.

Carbachol dimers with primary carbamate groups as homobivalent modulators of muscarinic receptors / Matucci R.; Bellucci C.; Martino M.V.; Nesi M.; Manetti D.; Welzel J.; Bartz U.; Holze J.; Trankle C.; Mohr K.; Mazzolari A.; Vistoli G.; Dei S.; Teodori E.; Romanelli M.N.. - In: EUROPEAN JOURNAL OF PHARMACOLOGY. - ISSN 0014-2999. - ELETTRONICO. - 883:(2020), pp. 1-9. [10.1016/j.ejphar.2020.173183]

Carbachol dimers with primary carbamate groups as homobivalent modulators of muscarinic receptors

Matucci R.;Bellucci C.;Nesi M.;Manetti D.;Dei S.;Teodori E.;Romanelli M. N.
2020

Abstract

Although agonists and antagonists of muscarinic receptors have been known for long time, there is renewed interest in compounds (such as allosteric or bitopic ligands, or biased agonists) able to differently and selectively modulate these receptors. As a continuation of our previous research, we designed a new series of dimers of the well-known cholinergic agonist carbachol. The new compounds were tested on the five cloned human muscarinic receptors (hM1–5) expressed in CHO cells by means of equilibrium binding experiments, showing a dependence of the binding affinity on the length and position of the linker connecting the two monomers. Kinetic binding studies revealed that some of the tested compounds were able to slow the rate of NMS dissociation, suggesting allosteric behavior, also supported by docking simulations. Assessment of ERK1/2 phosphorylation on hM1, hM2 and hM3 activation showed that the new compounds are endowed with muscarinic antagonist properties. At hM2 receptors, some compounds were able to stimulate GTPγS binding but not cAMP accumulation, suggesting a biased behavior. Classification, Molecular and cellular pharmacology.
2020
883
1
9
Goal 3: Good health and well-being for people
Matucci R.; Bellucci C.; Martino M.V.; Nesi M.; Manetti D.; Welzel J.; Bartz U.; Holze J.; Trankle C.; Mohr K.; Mazzolari A.; Vistoli G.; Dei S.; Teodori E.; Romanelli M.N.
File in questo prodotto:
File Dimensione Formato  
EJP_Matucci_2020.pdf

Accesso chiuso

Descrizione: lavoro pubblicato
Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 1.25 MB
Formato Adobe PDF
1.25 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1210138
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact